Atea PharmaceuticalsvsJohnson & Johnson

AVIR and JNJ stock compared: price, dividend, valuation and results, from SEC filings.

AVIR

Atea Pharmaceuticals, Inc.

$3.96

Value $316M

+0.76%
AVIR's page

Atea Pharmaceuticals (AVIR) has a market value of $316M and Johnson & Johnson (JNJ) $652B. Over the last year, with dividends, AVIR moved +25.7% and JNJ +36.6%. Dividend yield: AVIR none, JNJ 1.95%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    AVIR$316M

    JNJ$652B

    JNJ is 2,066 times AVIR

  • Revenue, 12 months

    AVIR–

    JNJ$99.3B

  • Net income, 12 months

    AVIR-$155M

    JNJ$16.1B

  • Operating margin

    AVIR–

    JNJ–

  • ROIC

    AVIR-51.9%

    JNJ12.4%

    64.3 points apart

  • P/E

    AVIR–

    JNJ40.5

  • Dividend yield

    AVIR0.0%

    JNJ2.0%

    2.0 points apart

  • 5-year return

    AVIR-51.2%

    JNJ+90.9%

    142.1 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

AVIR-51.2%

JNJ+90.9%

5010015020020222023202420252026
Returns by period
PeriodAVIRWith dividendsJNJWith dividends
1 year since November 19, 2025+25.7%Price +25.7%+36.6%Price +33.6%
3 years since November 20, 2023+31.6%+9.6% a yearPrice +31.6%+94.9%+24.9% a yearPrice +80.4%
5 years since November 19, 2021-51.2%-13.4% a yearPrice -51.2%+90.9%+13.8% a yearPrice +66.0%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

AVIRAtea PharmaceuticalsJNJJohnson & Johnson

Valuation

AVIRJNJ
Valuation
Price$3.96$270.47
Market value$316M$652B
Enterprise value (EV)$124M$679B
P/E–40.5
P/E, 5-year median–21.9
P/B1.88.0
EV/EBIT–38.3
Free cash flow yield–3.2%

Results and growth

AVIRJNJ
Results and growth
Revenue, 12 months–$99.3B
Net income, 12 months-$155M$16.1B
Free cash flow, 12 months-$141M$20.6B
Earnings per share, 12 months-$1.95$6.59
Revenue growth, year on year622.5%6.1%
Revenue growth a year, past+622.5%over 1 years+2.7%over 5 years
EPS growth a year, past–+14.9%over 5 years

Margins and returns on capital

AVIRJNJ
Margins and returns on capital
Gross margin–67.6%
Operating margin––
Net margin–16.2%
ROIC-51.9%12.4%
ROE-64.5%19.7%

Balance sheet

AVIRJNJ
Balance sheet
Cash$191M$17.2B
Total debt$213.0K$44.7B
Net debt / EBITDA–1.1
Interest cover–18.0×

Dividends and buybacks

AVIRJNJ
Dividends and buybacks
Dividend yield–2.0%
Dividend per share, 12 months–$5.28
Dividend growth a year, past–+5.3%over 5 years
Buyback yield8.1%0.9%
Shareholder yield8.1%2.9%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: AVIR or JNJ

Didn't find what you were looking for?

Ask us
Which is bigger, Atea Pharmaceuticals or Johnson & Johnson?

By market value, Johnson & Johnson ($652B) is about 2,065.9 times Atea Pharmaceuticals ($316M), at today's prices.

How did AVIR and JNJ stock do over the last 5 years?

Since November 19, 2021, AVIR's price moved -51.2% and JNJ's +66.0%. With dividends: AVIR -51.2% (-13.4% a year), JNJ +90.9% (+13.8% a year). Past returns do not predict future ones.

Which pays the higher dividend, AVIR or JNJ?

The dividend yield at today's price is none for Atea Pharmaceuticals and 1.95% for Johnson & Johnson. Over the last twelve months they paid – and $5.28 per share.

Which is the better investment, Atea Pharmaceuticals or Johnson & Johnson?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.